Skip to main content
Top
Published in: Inflammation 3/2014

01-06-2014

The Relationship Between Serum Lipoprotein (a) Levels and Ischemic Stroke Risk: A Cohort Study in the Chinese Population

Authors: Shao-yi Li, Yun Gao, Wei-ning Ma, Hua-chao Wang, Gang Zhou, Wen-chang Guo, Yun-hui Liu

Published in: Inflammation | Issue 3/2014

Login to get access

Abstract

The role of atherosclerosis in ischemic stroke has been intensively investigated in recent years, and lipoprotein (a) [Lp(a)] is found to have roles during the process. The aim of this study was to investigate the relationship between acute ischemic stroke (AIS) and serum Lp(a) levels in the Chinese population. All consecutive patients with first-ever acute ischemic stroke during 2011–2012 were recruited to participate in the study. Serum Lp(a) levels and routine tests were examined in both groups. The National Institutes of Health Stroke Scale (NIHSS) score was assessed on admission blinded to Lp(a) levels. In this study, 181 patients with acute ischemic stroke were included. There was a significant difference in median serum Lp(a) levels between acute ischemic stroke patients and control cases (328 [IQR, 173–554] vs. 145 [IQR, 66–254] mg/L, respectively; P = 0.000). Lp(a) levels increased with increasing severity of stroke as defined by the NIHSS score (P = 0.000). For the entire group, when adjusting for other possible risk factors, an elevated Lp(a) level was an independent risk factor for stroke, and a serum Lp(a) level ≥300 mg/L was associated with a 2.23-fold increase in AIS (P = 0.015). In addition, this association was stronger in male than in female patients. High Lp(a) levels are significantly related to stroke, independent from other traditional and emerging risk factors, suggesting that they may play a role in its pathogenesis. It should be considered as a routine risk factor for stroke in the Chinese population.
Literature
1.
go back to reference Vucković, B.A., M.J. Djerić, T.A. Ilić, V.B. Canak, S.L.J. Kojić-Damjanov, M.G. Zarkov, and V.S. Cabarkapa. 2010. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Srpski Arhiv za Celokupno Lekarstvo 138(1): 12–17.PubMed Vucković, B.A., M.J. Djerić, T.A. Ilić, V.B. Canak, S.L.J. Kojić-Damjanov, M.G. Zarkov, and V.S. Cabarkapa. 2010. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Srpski Arhiv za Celokupno Lekarstvo 138(1): 12–17.PubMed
2.
go back to reference Tu, W.J., X. Dong, S.J. Zhao, D.G. Yang, and H. Chen. 2013. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. Journal of Neuroendocrinology 25: 771–778.PubMedCrossRef Tu, W.J., X. Dong, S.J. Zhao, D.G. Yang, and H. Chen. 2013. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. Journal of Neuroendocrinology 25: 771–778.PubMedCrossRef
3.
go back to reference Unal, E., S. Mungan, S. Bilen, Y. Karadag, N. Oztekin, F. Bakir, and F. Ak. 2013. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. International Journal of Neuroscience 123: 532–536.PubMedCrossRef Unal, E., S. Mungan, S. Bilen, Y. Karadag, N. Oztekin, F. Bakir, and F. Ak. 2013. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. International Journal of Neuroscience 123: 532–536.PubMedCrossRef
4.
go back to reference Uno, M., K.T. Kitazato, K. Nishi, H. Itabe, and S. Nagahiro. 2003. Raised plasma oxidized LDL in acute cerebral infarction. Journal of Neurology, Neurosurgery and Psychiatry 74: 312–316.PubMedCentralPubMedCrossRef Uno, M., K.T. Kitazato, K. Nishi, H. Itabe, and S. Nagahiro. 2003. Raised plasma oxidized LDL in acute cerebral infarction. Journal of Neurology, Neurosurgery and Psychiatry 74: 312–316.PubMedCentralPubMedCrossRef
5.
go back to reference Nordestgaard, B.G., M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen. 2010. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31: 2844–2853.PubMedCentralPubMedCrossRef Nordestgaard, B.G., M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen. 2010. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31: 2844–2853.PubMedCentralPubMedCrossRef
6.
go back to reference Morishita, R., J. Ishii, Y. Kusumi, S. Yamada, N. Komai, M. Ohishi, M. Nomura, H. Hishida, M. Niihashi, and M. Mitsumata. 2009. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. Journal of Atherosclerosis and Thrombosis 16: 410–418.PubMedCrossRef Morishita, R., J. Ishii, Y. Kusumi, S. Yamada, N. Komai, M. Ohishi, M. Nomura, H. Hishida, M. Niihashi, and M. Mitsumata. 2009. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. Journal of Atherosclerosis and Thrombosis 16: 410–418.PubMedCrossRef
7.
go back to reference Rosas, S., M. Joffe, M. Wolfe, K. Brayman, and D.J. Rader. 2008. Effects of renal replacement therapy on plasma lipoprotein(a) levels. American Journal of Nephrology 28: 361–365.PubMedCentralPubMedCrossRef Rosas, S., M. Joffe, M. Wolfe, K. Brayman, and D.J. Rader. 2008. Effects of renal replacement therapy on plasma lipoprotein(a) levels. American Journal of Nephrology 28: 361–365.PubMedCentralPubMedCrossRef
8.
go back to reference Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J.L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263: 35–36.PubMedCrossRef Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J.L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263: 35–36.PubMedCrossRef
9.
go back to reference Wright, L.C., D.R. Sullivan, M. Muller, M. Dyne, M.H. Tattersall, and C.E. Mountford. 1989. Elevated apolipoprotein(a) levels in cancer patients. International Journal of Cancer 43: 241–244.CrossRef Wright, L.C., D.R. Sullivan, M. Muller, M. Dyne, M.H. Tattersall, and C.E. Mountford. 1989. Elevated apolipoprotein(a) levels in cancer patients. International Journal of Cancer 43: 241–244.CrossRef
10.
go back to reference Engler, H., and W.F. Riesen. 1993. Effect of thyroid function on concentrations of lipoprotein(a). Clinical Chemistry 39: 2466–2469.PubMed Engler, H., and W.F. Riesen. 1993. Effect of thyroid function on concentrations of lipoprotein(a). Clinical Chemistry 39: 2466–2469.PubMed
11.
go back to reference Milionis, H.J., V. Mittari, G. Exarchakos, R. Kalaitzidis, A.T. Skevas, and M.S. Elisaf. 2003. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. European Journal of Clinical Investigation 33: 1045–1050.PubMedCrossRef Milionis, H.J., V. Mittari, G. Exarchakos, R. Kalaitzidis, A.T. Skevas, and M.S. Elisaf. 2003. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. European Journal of Clinical Investigation 33: 1045–1050.PubMedCrossRef
12.
go back to reference Bernick, C., L. Kuller, C. Dulberg, et al. 2001. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57: 1222–1229.PubMedCrossRef Bernick, C., L. Kuller, C. Dulberg, et al. 2001. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57: 1222–1229.PubMedCrossRef
13.
go back to reference Safarova, M.S., M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky. 2013. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements 14: 93–99.PubMedCrossRef Safarova, M.S., M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky. 2013. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements 14: 93–99.PubMedCrossRef
14.
go back to reference Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 2219–2226.PubMedCentralPubMedCrossRef Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 2219–2226.PubMedCentralPubMedCrossRef
15.
go back to reference Smolders, B., R. Lemmens, and V. Thijs. 2007. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 38: 1959–1966.PubMedCrossRef Smolders, B., R. Lemmens, and V. Thijs. 2007. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 38: 1959–1966.PubMedCrossRef
16.
go back to reference Boden-Albala, B., D.E. Kargman, I.F. Lin, M.C. Paik, R.L. Sacco, and L. Berglund. 2010. Increased stroke risk and lipoprotein (a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovascular Diseases 30: 237–243.PubMedCentralPubMedCrossRef Boden-Albala, B., D.E. Kargman, I.F. Lin, M.C. Paik, R.L. Sacco, and L. Berglund. 2010. Increased stroke risk and lipoprotein (a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovascular Diseases 30: 237–243.PubMedCentralPubMedCrossRef
17.
go back to reference Ariyo, A.A., C. Thach, and R. Tracy. 2003. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef Ariyo, A.A., C. Thach, and R. Tracy. 2003. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef
19.
go back to reference Ohira, T., P. Schreiner, J. Morrisett, L. Chambless, W. Rosamond, and A. Folsom. 2006. Lipoprotein(a) and incident ischemic stroke: the Atherosclerotic Risk in Communities (ARIC) study. Stroke 37: 1407–1412.PubMedCrossRef Ohira, T., P. Schreiner, J. Morrisett, L. Chambless, W. Rosamond, and A. Folsom. 2006. Lipoprotein(a) and incident ischemic stroke: the Atherosclerotic Risk in Communities (ARIC) study. Stroke 37: 1407–1412.PubMedCrossRef
20.
go back to reference Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein (a) and coronary heart disease. Meta analysis of prospective studies. Circulation 102: 1082–1085.PubMedCrossRef Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein (a) and coronary heart disease. Meta analysis of prospective studies. Circulation 102: 1082–1085.PubMedCrossRef
21.
go back to reference Alfthan, G., J. Pekkanen, M. Jauhiainen, J. Pitkäniemi, M. Karvonen, J. Tuomilehto, J.T. Salonen, and C. Ehnholm. 1994. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9–19.PubMedCrossRef Alfthan, G., J. Pekkanen, M. Jauhiainen, J. Pitkäniemi, M. Karvonen, J. Tuomilehto, J.T. Salonen, and C. Ehnholm. 1994. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9–19.PubMedCrossRef
22.
go back to reference Ridker, P.M., M.J. Stampfer, and C.H. Hennekens. 1995. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269–1273.PubMedCrossRef Ridker, P.M., M.J. Stampfer, and C.H. Hennekens. 1995. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269–1273.PubMedCrossRef
23.
go back to reference Hatano, S. 1976. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 54: 541–553.PubMedCentralPubMed Hatano, S. 1976. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 54: 541–553.PubMedCentralPubMed
24.
go back to reference Katan, M., F. Fluri, and N.G. Morgenthaler. 2009. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Annals of Neurology 66: 799–808.PubMedCrossRef Katan, M., F. Fluri, and N.G. Morgenthaler. 2009. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Annals of Neurology 66: 799–808.PubMedCrossRef
25.
go back to reference Brott, T., J.R. Marler, C.P. Olinger, et al. 1989. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 20: 871–875.PubMedCrossRef Brott, T., J.R. Marler, C.P. Olinger, et al. 1989. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 20: 871–875.PubMedCrossRef
26.
go back to reference Adams Jr., H.P., B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, and E.E. Marsh 3rd. 1993. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.PubMedCrossRef Adams Jr., H.P., B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, and E.E. Marsh 3rd. 1993. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.PubMedCrossRef
27.
go back to reference Kamstrup, P.R., A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331–2339.PubMedCrossRef Kamstrup, P.R., A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331–2339.PubMedCrossRef
28.
go back to reference Matthews, K.A., M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak. 2005. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). American Heart Journal 149: 1066–1073.PubMedCrossRef Matthews, K.A., M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak. 2005. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). American Heart Journal 149: 1066–1073.PubMedCrossRef
29.
go back to reference Tu, W.J., S.J. Zhao, T.G. Liu, D.G. Yang, and H. Chen. 2013. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurological Research 35: 912–921.PubMedCrossRef Tu, W.J., S.J. Zhao, T.G. Liu, D.G. Yang, and H. Chen. 2013. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurological Research 35: 912–921.PubMedCrossRef
30.
go back to reference Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef
31.
go back to reference Kistorp, C., I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt. 2005. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609–1616.PubMedCrossRef Kistorp, C., I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt. 2005. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609–1616.PubMedCrossRef
32.
go back to reference Wiberg, B., J. Sundstrom, J. Arnlov, A. Terent, B. Vessby, B. Zethelius, and L. Lind. 2006. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. Stroke 37: 2898–2903.PubMedCrossRef Wiberg, B., J. Sundstrom, J. Arnlov, A. Terent, B. Vessby, B. Zethelius, and L. Lind. 2006. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. Stroke 37: 2898–2903.PubMedCrossRef
33.
go back to reference Dhamija, R.K., P. Gaba, S. Arora, A. Kaintura, M. Kumar, and J. Bhattacharjee. 2009. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. Journal of Neurological Sciences 281: 64–68.CrossRef Dhamija, R.K., P. Gaba, S. Arora, A. Kaintura, M. Kumar, and J. Bhattacharjee. 2009. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. Journal of Neurological Sciences 281: 64–68.CrossRef
34.
go back to reference Hachinski, V., C. Graffagnino, M. Beaudry, et al. 1996. Lipids and stroke paradox resolved. Archives of Neurology 53: 303–308.PubMedCrossRef Hachinski, V., C. Graffagnino, M. Beaudry, et al. 1996. Lipids and stroke paradox resolved. Archives of Neurology 53: 303–308.PubMedCrossRef
35.
go back to reference van Kooten, F., J. van Krimpen, D.W. Dippel, N. Hoogerbrugge, and P.J. Koudstaal. 1996. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 27: 1231–1235.PubMedCrossRef van Kooten, F., J. van Krimpen, D.W. Dippel, N. Hoogerbrugge, and P.J. Koudstaal. 1996. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 27: 1231–1235.PubMedCrossRef
36.
go back to reference Ariyo, A.A., C. Thach, and R. Tracy. 2003. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef Ariyo, A.A., C. Thach, and R. Tracy. 2003. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. New England Journal of Medicine 349: 2108–2115.PubMedCrossRef
37.
go back to reference Hajjar, K.A., and D. Gavish. 1989. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339: 303–305.PubMedCrossRef Hajjar, K.A., and D. Gavish. 1989. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339: 303–305.PubMedCrossRef
38.
go back to reference Boerwinkle, E., C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. Journal of Clinical Investigation 90: 52–60.PubMedCentralPubMedCrossRef Boerwinkle, E., C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. Journal of Clinical Investigation 90: 52–60.PubMedCentralPubMedCrossRef
39.
go back to reference Tascilar, N., S. Ekem, and E. Aciman. 2009. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in Turkish population. Tohoku Journal of Experimental Medicine 218: 293–300.PubMedCrossRef Tascilar, N., S. Ekem, and E. Aciman. 2009. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in Turkish population. Tohoku Journal of Experimental Medicine 218: 293–300.PubMedCrossRef
40.
go back to reference Rath, M., A. Niendorf, T. Reblin, M. Dietel, H.J. Krebber, and U. Beisiegel. 1989. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579–592.PubMedCrossRef Rath, M., A. Niendorf, T. Reblin, M. Dietel, H.J. Krebber, and U. Beisiegel. 1989. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579–592.PubMedCrossRef
41.
go back to reference Kim, B.S., H.S. Jung, O.Y. Bang, C.S. Chung, K.H. Lee, and G.M. Kim. 2010. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 212: 682–688.PubMedCrossRef Kim, B.S., H.S. Jung, O.Y. Bang, C.S. Chung, K.H. Lee, and G.M. Kim. 2010. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 212: 682–688.PubMedCrossRef
42.
go back to reference Von Depka, M., U. Nowka-Göttl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth. 2000. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96: 3364–3368. Von Depka, M., U. Nowka-Göttl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth. 2000. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96: 3364–3368.
43.
go back to reference Barre, D.E., O. Griscti, K.A. Mizier-Barre, and K. Hafez. 2005. Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia. Canada. Journal of Oleo Science 54: 347–354.CrossRef Barre, D.E., O. Griscti, K.A. Mizier-Barre, and K. Hafez. 2005. Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia. Canada. Journal of Oleo Science 54: 347–354.CrossRef
44.
go back to reference Dangas, G., R. Mehran, P.C. Harpel, et al. 1998. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. Journal of the American College of Cardiology 32: 2035–2042.PubMedCrossRef Dangas, G., R. Mehran, P.C. Harpel, et al. 1998. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. Journal of the American College of Cardiology 32: 2035–2042.PubMedCrossRef
45.
go back to reference Ohtahara, A., I. Hisatome, Y. Yamamoto, M. Furuse, K. Sonoyama, Y. Furuse, et al. 2001. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. Journal of Hypertension 19: 575–582.PubMedCrossRef Ohtahara, A., I. Hisatome, Y. Yamamoto, M. Furuse, K. Sonoyama, Y. Furuse, et al. 2001. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. Journal of Hypertension 19: 575–582.PubMedCrossRef
46.
go back to reference Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS 1992:10193–10197. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS 1992:10193–10197.
Metadata
Title
The Relationship Between Serum Lipoprotein (a) Levels and Ischemic Stroke Risk: A Cohort Study in the Chinese Population
Authors
Shao-yi Li
Yun Gao
Wei-ning Ma
Hua-chao Wang
Gang Zhou
Wen-chang Guo
Yun-hui Liu
Publication date
01-06-2014
Publisher
Springer US
Published in
Inflammation / Issue 3/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9785-x

Other articles of this Issue 3/2014

Inflammation 3/2014 Go to the issue